2008-11-09 12:10:01 -
www.hythiam.com - Hythiam, Inc. (NASDAQ:HYTM) announced today that the Company will present at the upcoming Rodman & Renshaw 10th Annual Healthcare Conference, to be held November 10-12, 2008, at The New York Palace Hotel in New York.
Terren Peizer, Chairman and Chief Executive Officer, Hythiam, will present on Monday, November 10th, at 5:45 p.m. Eastern Time. The presentation will
be available as a live, audio webcast at:
www.wsw.com/webcast/rrshq14/hytm/. Hythiam's webcast will also be available on its website at www.hythiam.com, where it will be archived for 14 days following the conference.
About Hythiam(R)
Hythiam, Inc. provides through its CatasysTM offering, behavioral health management services to health plans, employers and unions through a network of licensed and company managed healthcare providers. Catasys offers integrated substance dependence solutions built around the patented PROMETA(R) Treatment Program for alcoholism and stimulant dependence. The PROMETA Treatment Program, which integrates behavioral, nutritional, and medical components, is also available on a private-pay basis through licensed treatment providers and company managed treatment centers. Hythiam also researches, develops, licenses and commercializes innovative and proprietary physiological, nutritional, and behavioral treatment programs. Hythiam does not practice medicine or manufacture, distribute, or sell any medications and has no relationship with any manufacturers or distributors of medications used in the PROMETA Treatment Program. For further information, please visit www.hythiam.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history and lack of statistically significant formal research studies, the risk that treatment protocols might not be effective, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the healthcare industry; and additional risks factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at
www.sec.gov.
Investor Relations:
Hythiam, Inc.
Hasmik Bulujian, 310-444-4333
hbulujian@hythiam.com
or
Media Relations:
Dan Klores Communications
Tim Sullivan, 212-981-5234
tim_sullivan@dkcnews.com 
